Michelle L. Shuffett, MD, Senior Vice President of Medical and Scientific Affairs, RS BioTherapeutics

Michelle L. Shuffett, MD, joined RS BioTherapeutics, a biopharmaceutical company with a mission to harness the therapeutic power of anti-inflammatory cannabinoids in the research, development, and commercialization of life-changing medications, in May as Senior Vice President of Medical and Scientific Affairs. As part of that role, she will support the ongoing pre-clinical development program, drive publication planning, lead KOL engagement efforts, and help facilitate the IND submission and subsequent initiation of the clinical development program.

Dr. Shuffett attended medical school at the University of Kentucky, completed her residency at UCLA Mattel Children's Hospital, and practiced at Children's Hospital Los Angeles. She began her career in the pharmaceutical industry at Boehringer Ingelheim, focusing on COPD opinion leader development and advocacy, medical marketing communications, research, and medical-legal review. During that time, she also attended the London School of Economics and earned certifications in Healthcare Economics and Quantitative Analysis.

Dr. Shuffett has also served in senior leadership roles at several organizations including Columbia Care, Radicle Science, Synapse Medical Communications, and Everyday Health. She founded her own consulting firm, Sea Sprite International Ltd. in 2018, and currently serves as an advisory board member for the 100 Million Ways Foundation and Maavee.